Objective: We aim to present a case report of abdominal wall dyskinesia as a tardive syndrome of prochlorperazine.

Background: The clinical presentation of involuntary choreiform movement of the anterior abdominal wall was first introduced as “belly dancer’s dyskinesia” in 1990. Tardive dyskinesia, trauma, or pain of the affected region may be causative factors.

Method: Written informed consent for publication was obtained from the patient.

Results: We report a case of orobuccal stereotypic movements and abdominal wall dyskinesia secondary to prochlorperazine intake. The movements began 2 weeks after cessation of prochlorperazine. The patient took this dopamine receptor-blocking medication for 6 months to treat nausea due to chemotherapy. 
He was diagnosed with cardiac amyloidosis for which he began chemotherapy in January 2019. Chemotherapeutic agents included cyclophosphamide, daratumumab, elotuzumab, and bortezomib. Due to the side effects of nausea and vomiting, the patient was prescribed prochlorperazine (Compro) 5-mg tablets in February 2019.
The patient was a somewhat poor historian, as he initially reported that he occasionally would take 20 tablets in 1 day, but later reported that he would take 4–6 tablets per day. After chemotherapy had concluded in May 2019, the patient reported he would still take prochlorperazine as needed for prophylaxis against nausea for a total of six months of exposure. Pharmacy records showed that the patient obtained prochlorperazine from two different providers at two different pharmacies, which summed up to 1,620 obtained tablets over the course of 6 months.

Conclusion: The importance of keeping track of length of exposure to neuroleptics is demonstrated in. this case. Doctor shopping may obscure the total amount of medication dispensed and lead to undesirable side effects.

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/belly-dancers-dyskinesia-due-to-prochlorperazine/